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A series of synthetic peptides corresponding to segments of HIV encoded proteins were selected using criteria described 
by Welling et al. [(1985) FEBS Lett. 188, 2151. Synthetic peptide analogs to gp120 (2-13) (5565), gp41 (582-596) (659- 
670) and tat,,, (71-83) were recognized by 4167% of sera or plasma from individuals known to be infected with HIV 
on the basis of virus isolation or Western blot screening. The pcptide which reacted with most sera or plasma was gp41 
(582-596), a conserved region in the transmembrane glycoprotein. An extended peptide analog, gp41 (579-599) tested 
against the same samples showed almost 100% reactivity, confirming independent studies identifying a highly immuno- 
dominant region of gp41. There was an unexpected high prevalence of antibodies (52%) to the tat,,, peptide. 
HIV; Tat,,,; Predicted antigenicity; Antibody response; Synthetic peptide 
1. INTRODUCTION 
Infection with human immunodeficiency virus 
(HIV) has been traditionally confirmed by detec- 
ting antibodies against proteins derived from par- 
tially purified virus or antigens synthesized in 
virus-infected cells [l]. As these preparations con- 
tain some non-viral antigen, problems of specifici- 
ty have been encountered. To overcome these 
difficulties considerable interest has arisen in the 
use of synthetic peptides and recombinant proteins 
[2-81 which might only detect antibodies directed 
against antigenic sites on HIV. A variety of 
algorithms have been proposed for predicting an- 
tigenic epitopes [9-l 11. Recently Welling et al. [12] 
suggested an empirical method based on the fre- 
quency of occurrence of amino acids in known an- 
tigenic regions of some well characterized proteins. 
Using this procedure, several potential antigenic 
epitopes have been identified in the envelope 
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glycoproteins gp120 and gp41 as well as the tatm 
gene product of HIV-l. Synthetic peptides of 
11-21 residues corresponding to these regions were 
recognized by antibodies in sera or plasma from 
viraemic patients. 
2. MATERIALS AND METHODS 
2.1. Synthesis 
Peptides were synthesized by the Merrifield procedure 1131 
with the aid of an automated Applied Biosystems synthesizer 
using double coupling cycles supplied by the manufacturer. The 
N-t-butyloxcarbonyl amino acid derivatives were obtained from 
the Protein Research Foundation (Osaka, Japan). Side chain 
protection was the same as those supplied by Applied 
Biosystems with the exception of arginine for which the w-NO2 
derivative was used. Chain assembly was monitored using 
ninhydrin [ 141. Peptides were synthesized with a carboxyl or 
amino terminal cysteine to facilitate conjugation to proteins, 
often important for raising antisera to the peptide. The 
assembled peptides were simultaneously cleaved and 
deprotected using anhydrous HF containing 10% anisol (v/v) 
[15]. The peptide was precipitated with diethylether and washed 
with ethylacetate before extracting with 60% acetonitrile and 
0.1% trifluoroacetic acid (v/v). Previously we have used acetic 
acid to extract peptides; however, extraction with the common- 
ly used HPLC solvents results in improved purity. Synthetic 
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peptides were purified by preparative reversed phase HPLC 
(25 mm x 400 mm, C18, 250 A Amicon resin with a gradient 
of 1000 ml, O-60% acetonitrile in 0.1% trifluoroacetic acid 
over 15 h). The synthetic peptides were approx. 95% pure as 
judged by analytical reversed phase HPLC (Brownlee RP 300 
column 4.6 x 50 mm, O-60% acetonitrile in 0.1% 
trifluoroacetic acid at 1 ml/min over 30 min) and by quan- 
titative amino acid analysis following acid hydrolysis. 
Peptide analogs synthesized were gp120 (2-13) 
RVKEKYQHLWRC, gp120 (55-65) ASDAKAYDTEV, gp41 
(582-596) AVERYLKDQQLLGIC, gp41 (659-670) ELLELD- 
KWASLC, and tatrrr (71-83) SQTHQVSLSKQPC. The ex- 
tended gp41 peptide synthesized for comparisons to published 
data was gp41 (579-599) RILAVERYLKDQQLLGIWGCS. 
2.2. Plasma and serum specimens 
The panels of plasma and sera used were selected from 
samples submitted to the State and National HIV Reference 
Laboratories, Fairfield Hospital, Melbourne. Samples were 
selected so that patients in various stages of disease were 
represented. Infection with HIV-l had been confirmed by virus 
isolation from associated peripheral blood lymphocytes [16] or 
serology using a Western blotting procedure [17]. There were 44 
culture positive plasma and 42 Western blot positive sera. Se- 
quential plasma specimens were available for 2 patients both in 
advanced stages of disease. 
2.3. Enzyme immunoassay (EIA) 
Wells of polyvinyl plates (96 well Nunc Immunoplates) were 
coated with 100 ,uI peptide solution (10 pg/ml in carbonate buf- 
fer, pH 9.6) and held overnight at 4°C. The plates were washed 
10 times in phosphate-buffered saline (PBS) containing 0.05% 
Tween 20 and 0.01% NaN3. Non-specific adsorption was block- 
ed with PBS/l% bovine serum albumin (BSA) for 1 h at 37°C 
(2OOpl/well) and the plates were rewashed 10 times. A 1:50 
dilution of serum or plasma was added (lOOpl/well) and the 
plates incubated at 37°C for 1 h. The plates were again washed 
and 100 Fl/well of a 1: 80 dilution of alkaline phosphatase con- 
jugated rabbit anti-human IgG (Behring Enzygnost) was added 
and plates incubated for 45 min at 37’C. After washing the 
plates in washing buffer, distilled water, alkaline phosphatase 
substrate (2 mg/ml) in diethanolamine buffer was added and 
incubated for 30 min at room temperature. The reaction was 
stopped with 1.5 M NaOH and the wells read using a microtiter 
plate reader. 
3. RESULTS 
3.1. Predicted antigenic epitopes 
The sequence data for the HIV-l envelope pro- 
tein, gp160, was examined [18] using the Welling 
antigenicity program [12] and a number of poten- 
tial antigenic epitopes were identified (fig.lA). 
Epitopes present in regions considered as variable 
according to published comparisons of nucleotide 
sequences [191, or containing glycosylation sites 
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Fig.1. Profiles of HTLV IIIb env (a) and tatm (b) gene 
predicted amino acid sequences using the Welling program. 
Positions of the five synthetic peptide analogs tested are marked 
and labelled 1, gp120 (2-13); 2, gp120 (55-65); 3, gp41 
(582-596); 5, gp41 (659-670); and 6, tatm (71-83). 
sponding to the envelope protein sequence were 
synthesized, gp120 (2-13), (Pi-65), gp41 
(582-596) and (659-670). The tatm protein se- 
quence was similarly examined (fig.lB) and the 
peptide tatm (71-83) synthesized. 
3.2. Serological response to the synthetic peptide 
analogs 
Each of the five synthetic peptides were 
recognized by some of the plasma or sera tested 
from the three categories (healthy seropositive, 
ARC and full blown AIDS) (fig.2). Reaction to the 
peptides varied from patient to patient with some 
sera or plasma recognizing all five and others 
recognizing only one. There was no clear correla- 
tion to disease status with the exception of gp41 
(582-596). Antibodies against gp41 (582-596) 
were most frequently detected in the sera of 
healthy seropositive patients (15/16, 94%) but less 
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Fig.2. Combined values of 86 samples (42 sera and 44 plasma) 
tested by reactivity to five synthetic peptide analogs [l, gp120 
(2-13); 2, gp120 (S-65); 3, gp41 (582-596); 5, gp41 
(659-670); and 6, tatm (71-83)], plus samples that were also 
tested against the extended peptide labelled 4, gp41 (579-599). 
The cut off value was determined as the mean of seronegative 
control sera (5) plus 2 standard deviations. The sample/cutoff 
ratio for the EIA test is that value plotted for each sample. The 
number of positive samples/total number tested were 44186, 
40/86, 58/86, 19/19, 35/82 for peptides 1, 2, 3, 4, 5 and 6, 
respectively. 
commonly in patients with ARC/LAS (1 l/16, 
69%) and AIDS (29/45, 64%). Ten samples (12%) 
did not have detectable antibodies to any of the 
five synthetic peptides and of these 8 were from 
AIDS patients and 2 were from patients with ARC 
or LAS. Only 10 patients had antibodies to all five 
peptides and of these 8 were patients with AIDS. 
3.3. Serological response to an extended gp41 
peptide 
Wang and others [8] have reported a synthetic 
peptide encompassing gp41 (582-596), which 
reacted specifically with antibodies in serum from 
AIDS, ARC and asymptomatic carriers. We 
therefore synthesized an extended peptide, gp41 
(579-599), and directly compared it and gp41 
(582-596) using a second panel of 60 samples 
(comprising sera collected from 36 patients with 
AIDS, 17 with ARC/LAS and 3 healthy 
seropositive individuals). Whereas gp41 (582-596) 
was recognized by only 40 of the sera (67%) the ex- 
tended peptide gp41 (579-599) was recognized by 
all but 1 sample, which was from a patient with ter- 
minal AIDS. 
4. DISCUSSION 
Several approaches have been used to identify 
immunodominant epitopes for HIV-l envelope 
gene products [3-6,8]. These have used a process 
of elimination using recombinant peptide antigens 
[3-51 or involved the synthesis of a large number 
of synthetic peptide analogs over a large region of 
the genome (3 of 10 [8]; 3 of 17 [6]). We identified 
five synthetic peptide analogs that were recognized 
by antibodies in 41-67% of sera or plasma from 
patients positive for HIV culture or serology. Thus 
by using the Welling program to identify potential 
antigenic epitopes and additional criteria of con- 
servation among isolates, and excluding glycosyla- 
tion sites we were able to identify five, out of five 
tested, antigenic epitopes. Additionally gp41 
(582-596) was found to be part of a region 
recognized by almost 100% of patients sera, 
regardless of disease status. 
The extended peptide gp41 (579-599) was 
recognized by antibodies in 59 out of 60 samples 
from patients varying in disease status. One patient 
with AIDS did not recognize this peptide. We con- 
cur with the conclusions of Wang et al. [8] who 
found 93.6 of ARC and 98.3% of AIDS patients 
sera recognized gp41 (579-599). The shorter pep- 
tide, gp41 (582-596) was recognized more by an- 
tibodies from healthy seropositives (94%) than by 
those with ARC or AIDS (59% and 67% respec- 
tively). 
When peptide analog gp41 (582-596) 
[AVERYLKDQQLLGIC] is compared to peptide 
analogs synthesized by Wang et al. [8], gp41 
(579-599) [RILAVERYLKDQQLLGIWGCS], 
and Gnann et al. [6], gp41 (593-604) [LGLW- 
GCSGKLIC], there would appear to be at least 
two antigenic sites, one within gp41 (582-596) 
which may be focussed around the lysine at posi- 
tion 588 (see Wang et al. [S]), and a second within 
gp41 (593-604) possibly focussed around the tryp- 
tophen at position 596 (see [7]). 
Interestingly the recognition of a tatm peptide 
(71-83) by 52% of patients sera is much greater 
than recognition of the tatm protein in AIDS pa- 
tients reported elsewhere [21] (Sodroski, J., per- 
sonal communication). This peptide spans amino 
acids coded by the region immediately 5 ’ to the 
putative splice site between the second and the 
third exons of tatm mRNA [22] and covers some 
395 
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15% of the length of this critical regulatory pro- 
tein. No clinical correlates were apparent for pa- 
tients whose sera recognized this analog, but the 
central role of this protein in regulation of viral 
replication warrants further mapping of im- 
munodominant regions. 
Although this approach was useful in predicting 
native antigenic regions in HIV envelope and tatm 
proteins, more detailed studies of these regions are 
needed to fully define the antigenic epitope(s), as 
shown here for gp41 (582-596) which comprised 
part of a highly immunodominant region of gp41 
PI. 
Development of a sensitive and specific synthetic 
peptide diagnostic assay for HIV antibodies re- 
quires that conserved epitopes are universally 
recognized. We have shown declining reactivity to 
immunodominant epitopes in some patients with 
advanced disease (McPhee, D.A., unpublished 
results), and conclude that a reliable assay will re- 
quire more than a single synthetic peptide to reach 
necessary sensitivity standards. 
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